Nav: Home

Mapping residual esophageal tumors -- a glimpse into the future?

January 10, 2019

Osaka, Japan - It's one of the first questions asked by many newly-diagnosed cancer patients--"What are my chances of beating this?" Often there is no clear answer, with survival rates differing widely depending on the cancer stage and available treatment options. However, post-operative testing that provides an accurate prediction of long-term treatment outcomes is the next best thing to a crystal ball, allowing clinicians to plan further treatment or follow-up strategies and more accurately inform patients about their prognoses.

But is this possible? Researchers in Japan think that it might be, at least for esophageal cancer patients. In a recent study published in Annals of Surgery, a team led by researchers at Osaka University retrospectively examined tissue specimens from 120 esophageal cancer patients following treatment, allowing them to both assess tumor characteristics and investigate how these related to long-term treatment outcomes.

Esophageal cancer is the sixth most common cause of cancer-related death worldwide and, despite various treatment options, has a poor long-term prognosis. Most locally-advanced esophageal cancers are treated with neoadjuvant chemotherapy (NAC), which aims to increase the likelihood of successful curative surgery by reducing tumor size and eradicating systemic micro-metastases. Tissue specimens are usually examined after surgery to assess how a tumor has responded to chemotherapy treatment. However, standard methods do not map the remaining tumor cells to the different layers of the esophageal wall, and therefore provide an incomplete picture of treatment outcome.

The team hypothesized that there might be specific patterns of residual tumors after NAC, and that they might have different clinical implications for patients

The researchers therefore mapped the exact locations of residual tumors in the esophageal wall of patients after NAC and assessed whether tumor location was associated with clinicopathological parameters including specific oncological outcomes.

After NAC, they identified four tumor remnant patterns that are clearly different from those reported previously; the most common residual tumor pattern was a 'shallow type.' However, in approximately 40% of cases, tumor cells unexpectedly disappeared in the superficial (mucosal) layer of the esophageal wall, indicating that it would be difficult to diagnose whether or not tumor cells completely disappeared after NAC based only on an endoscopic mucosal biopsy. When the team examined associations between these patterns and disease factors, including prognosis, they found that pattern types 3 and 4 had higher risks of pleural dissemination and distant metastases than types 1 or 2. These results shows that patients displaying patterns 3 or 4 should have more regular follow-up appointments than those with pattern types 1 or 2. Interestingly, survival was similar among the four groups.

According to lead authors Tadayoshi Hashimoto and Tomoki Makino, these findings have significant clinical implications. They explained that by determining the tumor remnant pattern from resected specimens and post-operative image examination, a personalized treatment plan for each patient can be developed. This customized approach is expected to significantly improve esophageal cancer treatment outcomes.
-end-
The article, "The pattern of residual tumor after neoadjuvant chemotherapy for locally advanced esophageal cancer and its clinical significance", was published in Annals of Surgery at doi: https://doi.org/10.1097/SLA.0000000000003129.

About Osaka University

Osaka University was founded in 1931 as one of the seven imperial universities of Japan and now has expanded to one of Japan's leading comprehensive universities. The University has now embarked on open research revolution from a position as Japan's most innovative university and among the most innovative institutions in the world according to Reuters 2015 Top 100 Innovative Universities and the Nature Index Innovation 2017. The university's ability to innovate from the stage of fundamental research through the creation of useful technology with economic impact stems from its broad disciplinary spectrum.

Website: https://resou.osaka-u.ac.jp/en/top

Osaka University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...